A qualitative study of 30 Thai medicinal cannabis users finds they perceive CBD oil as beneficial and safe, but rely almost entirely on informal peer networks for guidance rather than healthcare providers. These findings illuminate a significant health information gap in Thailand’s post-decriminalization landscape, though they cannot be taken as evidence that cannabis is clinically effective for any condition.

Thailand decriminalized cannabis for medical use in 2019, creating a rapidly evolving regulatory environment where patient demand far outpaces both clinical evidence and provider training. Older adults with cancer, chronic pain, and other serious conditions are making daily treatment decisions with little formal guidance. This study shines a light on the informal information ecosystems that have filled the gap left by unprepared healthcare systems, raising urgent questions about patient safety, drug interactions, and the quality of unregulated products reaching some of the most vulnerable patients.

Thailand’s 2019 decriminalization of cannabis for medical purposes created a rapidly expanding but loosely regulated landscape in which patients began seeking cannabis products for conditions ranging from cancer to chronic pain and insomnia. This qualitative study interviewed 30 current medicinal cannabis users recruited through a single informal cannabis producer’s clinic and associated social networks in Bangkok. Using phenomenological in-depth interviews lasting 30 to 45 minutes, supplemented by participant observation, the researchers aimed to understand how Thai users perceive and experience medicinal cannabis. The study is grounded in the recognition that subjective patient experiences shape treatment adherence and information-seeking, regardless of what clinical trials may or may not demonstrate.

Three themes emerged from thematic analysis: participants perceived cannabis as beneficial for managing a wide range of symptoms and conditions, viewed it as natural and therefore safe compared to pharmaceutical medications, and identified a significant need for more reliable information. Notably, participants obtained nearly all their cannabis-related knowledge from peer users via online chat groups rather than from healthcare providers, who were perceived as lacking expertise in cannabis therapeutics. The study’s primary limitations include exclusive recruitment from a single producer’s network, absence of negative case analysis or reflexivity reporting, and a sample heavily skewed toward older women with cancer. The authors acknowledge that further research, including multi-site studies and clinical outcome investigations, is needed to move beyond perception data toward actionable clinical evidence.

Filling the Vacuum: How Informal Networks Became the Medical Cannabis Experts in Thailand

In Bangkok, a man named Somchai runs a cannabis clinic from his home. Every day, patients, mostly older women, many with cancer, stop by to pick up small amber bottles of cannabis extract oil, then call him with questions that their doctors could not answer. This is not a failure of the patients’ judgment. It is a failure of a system that legalized a treatment without building the infrastructure to support it. This paper, at its best, documents exactly that gap. It captures something honest about how medicine works in the real world: patients do not wait for randomized trials before making treatment decisions. They act on hope, on peer experience, on what feels natural and accessible. And when formal healthcare providers have nothing to offer, patients build their own networks. The study’s ecological embedding, with the researcher observing actual interactions at the producer’s home clinic, adds a layer of lived-world texture that pure interview studies rarely achieve. That is a genuine contribution. But the study also illustrates the core challenge of qualitative work done in a single node of a self-selected network. Recruiting only current, active users at one producer’s clinic is like asking only the diners still seated at a restaurant whether the food is good. You will never hear from those who left after the first course or got food poisoning. There is no negative case analysis, no effort to reach people who tried cannabis and stopped, no reflexivity about conducting the research with the producer’s cooperation in the producer’s space. The result is a portrait of satisfaction that may be genuine for these 30 individuals but cannot be generalized.

The paper’s most important contribution is not about cannabis pharmacology. It is about information architecture. These participants, predominantly older adults managing cancer and chronic conditions, are getting dosing advice from online chat groups. They are making decisions about whether to continue or replace conventional oncology treatments based on what a trusted peer said in a group message. For a clinician, this is where the alarm bells ring. We are not just talking about a lifestyle product. We are talking about unregulated preparations with unknown cannabinoid profiles being used alongside chemotherapy regimens, with no one checking for drug interactions, no one monitoring hepatic enzyme induction, and no one documenting adverse events that were never reported because the study never asked about them. The paper describes participants perceiving cannabis as natural and therefore safe, a belief the researchers documented but did not critically examine. A patient feeling better after taking a remedy tells us something important about their experience, but it does not tell us whether the remedy did the work, or whether they would have felt better anyway. And studying the effects of “CBD oil” without knowing whether participants received standardized product or something closer to artisanal homebrew is like studying the effects of “wine” without knowing whether they drank a glass of rose or a bottle of port. The label is the same, but what is inside matters enormously.

What would I say to a patient? That their experiences matter, that I want to understand what they are taking, and that some of the information circulating in chat groups about cannabis curing cancer has not been validated by any clinical trial. What would I say to a colleague? That this paper is useful for understanding why our patients are seeking cannabis outside of clinical channels, but that it cannot and should not be cited as evidence that cannabis treats cancer, pain, or insomnia. What would I say to a policymaker? That Thailand, like every country navigating cannabis reform, must decide whether to meet patients where they are or leave them in the hands of informal producers, however well-intentioned those producers may be. This study is a window into a universal phenomenon: when formal medicine leaves a vacuum, patients fill it themselves, with peer wisdom, online communities, and trusted informal sources. The experiences these 30 participants described are real and deserve respect. But experiencing relief and receiving effective treatment are not always the same thing, and the information ecosystem sustaining these patients carries risks of unregulated product quality, drug interactions, and beliefs about cannabis curing cancer that no clinical trial has validated. The study’s real contribution is not about cannabis. It is about health system design, and the durable lesson is clear: when healthcare systems fail to provide guidance on emerging treatments, patients build their own information ecosystems, and those ecosystems may be based on belief rather than evidence.

This study sits at the earliest point in the research arc for Thai medical cannabis: it captures user perceptions before clinical outcome studies have been conducted in this population. For clinicians working in medical cannabis, its value lies not in validating any therapeutic claim but in documenting the reality that patients are already deeply engaged with cannabis products and are making consequential decisions with information sourced almost entirely outside regulated healthcare channels. The finding that peer networks have become the default source of dosing and safety information is consistent with qualitative research from other post-legalization contexts, including North America and Israel, and underscores a structural problem that transcends any single regulatory environment.

The pharmacological and safety implications deserve particular attention. These participants were predominantly older adults with cancer, a population at elevated risk for drug interactions between cannabinoids and common oncology medications, including those metabolized through CYP3A4 and CYP2C9 pathways. The products used were unregulated CBD oil extracts with no reported standardization or third-party testing, meaning both cannabinoid content and contaminant risk are unknown. For clinicians, the single most actionable recommendation from this study is straightforward: proactively ask patients about cannabis use, especially older patients managing cancer or chronic pain, and document what they are taking so that potential drug interactions can be identified before they cause harm.

This is a primary descriptive qualitative study using phenomenological in-depth interviews and thematic analysis. In the evidence hierarchy, qualitative research generates hypotheses and explores lived experience; it does not establish causal relationships, measure clinical outcomes, or demonstrate efficacy. The single most important inference constraint is that participant-reported perceptions of benefit are subjective data about experience, not evidence that cannabis is effective or safe for any medical condition.

The findings align with qualitative work from other post-legalization settings showing that patients commonly perceive cannabis as natural and safe, prefer peer-sourced information over formal medical guidance, and report broad perceived benefits across multiple conditions. The study by Sukrueangkul and colleagues (2022) on Thai cancer patients’ beliefs about cannabis similarly documented a strong perceived-benefit narrative among users, though also in a non-clinical framework. Schlag and colleagues (2021) and Minerbi and colleagues (2019) offer a counterbalance, highlighting the risks of medicinal cannabis, including drug interactions in older adults, that this study’s design was not equipped to detect. The present study extends these threads by documenting the specific informal distribution and information architecture that has emerged in Thailand’s post-decriminalization period, adding contextual detail to a growing literature on the gap between patient demand and healthcare system preparedness.

The most consequential analytic choice was the exclusive recruitment of current, active cannabis users from a single producer’s clinic without any effort to include former users, those who experienced adverse effects, or those who discontinued use. Had the researchers employed maximum variation sampling, deliberately recruiting users from multiple access points including formal medical channels, as well as former users who stopped for any reason, the thematic landscape would almost certainly have included themes of dissatisfaction, side effects, and unmet expectations. Additionally, the absence of negative case analysis means the researchers did not systematically search their data for disconfirming evidence, a standard qualitative rigor technique that could have produced a more balanced and credible thematic structure even within the existing sample.

The most likely and most consequential misreading of this study is the claim that it demonstrates cannabis is effective for cancer, pain, or insomnia. It does not. The study documents what 30 users believe, not what cannabis does clinically. Perceived benefit reported in qualitative interviews is a fundamentally different category of evidence from measured clinical outcomes in a controlled trial. This distinction is especially critical for the cancer subgroup, a population already vulnerable to unproven treatment claims. Similarly, the finding that participants view cannabis as natural and safe should not be interpreted as evidence of safety; naturalness is a perception, not a pharmacological property, and these products were unregulated, of unknown composition, and used alongside conventional treatments with no interaction monitoring.

This study contributes a contextually grounded account of how one network of Thai medicinal cannabis users perceives, accesses, and seeks information about cannabis in the years following decriminalization. It does not establish efficacy, safety, or broad representativeness. Its most durable contribution is documenting the information vacuum that formal healthcare has left unfilled, and the informal patient ecosystems that have risen to fill it. For clinicians, the practical message is not about cannabis itself but about the urgent need to ask patients what they are taking and to provide reliable guidance before someone else does.

Does this study prove that cannabis works for cancer or chronic pain?

No. This study records what 30 users believe about their own experience. It did not measure clinical outcomes, compare cannabis to any other treatment, or track disease progression. Perceived benefit and demonstrated clinical efficacy are different categories of evidence, and this study provides only the former.

Is CBD oil safe because it is natural?

The participants in this study believed so, but naturalness does not determine safety. The CBD oil products used were unregulated, of unknown composition, and were taken alongside other medications, including cancer treatments, with no monitoring for drug interactions. Many natural substances carry significant pharmacological risks.

Can I rely on information from online cannabis communities for dosing guidance?

The study highlights that these communities have become the primary information source for many users precisely because healthcare providers have not stepped into that role. While peer support can be valuable, dosing decisions for medicinal cannabis, particularly in people taking other medications, should ideally involve a knowledgeable healthcare provider who can account for individual health conditions and potential drug interactions.

Are these findings relevant outside of Thailand?

The specific regulatory and cultural context is Thai, but the underlying dynamic, patients seeking cannabis guidance from informal networks because formal medicine has not kept pace with policy changes, has been documented in North America, Israel, and other post-legalization settings. The information gap is a global phenomenon, even if its details vary by country.

Have thoughts on this? Share it: